Serenate per 16 bionde

Biond Biologics Announces a Joint Poster Presentation With Sanofi at The ASCO 2022 Annual Meeting Presenting Pre-Clinical Translational Data of SAR444881 (BND-22)

Retrieved on: 
Tuesday, May 31, 2022
Myelocyte, Annual general meeting, VP, Enzyme, Tumor microenvironment, CD28, Sanofi, Patient, Poster, Phagocytosis, PD-1, Antibody, MHC, Society, American Society of Clinical Oncology, ILT2, Spatial planning, ILT3, Cell, Immunoglobulin G, Biomarker, ASCO, Escape Room, Protein, Cancer, LILRB1, Pharmaceutical industry, Vaccine, Serenate per 16 bionde

The poster presents pre-clinical translational data including potential patient enrichment biomarkers for SAR444881 (BND-22).

Key Points: 
  • The poster presents pre-clinical translational data including potential patient enrichment biomarkers for SAR444881 (BND-22).
  • The poster will be presented at:
    Abstract Title: Evaluation of pharmacodynamic and patient enrichment biomarkers for SAR444881, a first-in-class anti-ILT2 monoclonal antibody for cancer immunotherapy.
  • Leukocyte Ig-like receptor B1 (LILRB1), also known as immunoglobulin-like transcript 2 (ILT2), is an inhibitory receptor expressed on various immune cells.
  • "We previously demonstrated that SAR444881 has robust macrophage and lymphocyte-driven anti-tumor activity in in vitro and in vivo models.

Biond Biologics to Present at the Raymond James LILRB/ILT Symposium

Retrieved on: 
Wednesday, April 20, 2022
Protein, ILT2, Myelocyte, Tumor microenvironment, Enzyme, PD-1, CD28, Antibody, Sanofi, Serenate per 16 bionde, ILT3, Spatial planning, Escape Room, Patient, Cell, Vaccine

Biond Biologics is a clinical stage company focused on developing innovative therapies for novel oncology targets by uncovering immunoregulatory pathways and by enabling the intracellular delivery of biologics.

Key Points: 
  • Biond Biologics is a clinical stage company focused on developing innovative therapies for novel oncology targets by uncovering immunoregulatory pathways and by enabling the intracellular delivery of biologics.
  • Biond aims to translate high quality science and out-of-the-box disruptive thinking into transformational drugs for diseases with high unmet needs.
  • The company's vision is to deliver innovative medicines to patients while fostering synergistic long-term collaborations with leading biopharmaceutical companies.
  • The company is also developing BND-35 an ILT3 blocking antibody, that targets suppressive myeloid cells in the tumor microenvironment.